Agendia
Amsterdam
About Agendia
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $182.3M
- Funding stage: Private Equity
- Last round: Private Equity (Jul 2018)
- Website: agendia.com
- Phone: (204) 621-500_
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/agendia-71787 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.